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Abstract
Rationale, aims and objectives DEPICT (Descriptive Elements of Pharmacist Interven-
tion Characterization Tool) was created in response to the frequently reported issue of poor
intervention description across studies assessing the impact of clinical pharmacy activities.
The aim of this study was to create an improved version of DEPICT (i.e. DEPICT 2) to
better characterize clinical pharmacy services in order to ensure consistent reporting,
therefore enhancing reproducibility of interventions in practice.
Method A qualitative approach through a thematic content analysis was performed to
identify components of pharmacist interventions described in 269 randomized controlled
trials. A preliminary version of DEPICT 2 was applied independently by two authors to a
random sample of 85 of the 269 RCTs and reliability determined by the prevalence-
adjusted bias-adjusted kappa (PABAK) or the intraclass correlation coefficient (ICC). The
final version of DEPICT 2 was compared against DEPICT 1.
Results The final version of DEPICT 2 comprised 146 items and 11 domains. The inter-
rater agreement analysis showed that DEPICT presented good to optimal reproducibility,
with a mean PABAK value of 0.87 (95% CI 0.85–0.89) and a mean ICC value of 0.88 (95%
CI 0.62–1.14). The mean difference between items checked in the two versions (DEPICT
2 – DEPICT 1) was 10.58 (95% CI 9.55–11.61), meaning that approximately 11 more
components were identified in the new version of DEPICT.
Conclusions DEPICT 2 is a reliable tool to characterize components of clinical pharmacy
services, which should be used to ensure consistent reporting of interventions to allow their
reproducibility in practice.
Introduction
The literature has repeatedly attempted to demonstrate the impact
of clinical pharmacy services in patient health outcomes in several
medical conditions through systematic reviews and meta-analyses
[1,2]. It is common to report study heterogeneity in meta-analyses
as a means of assessing the variability among studies, either in
terms of participants, interventions, outcomes studied and study
design, or with regards to variability in the intervention effects
being evaluated in the different studies [3]. In the pharmacy prac-
tice literature, several meta-analyses showed heterogeneities over
50%, which is the cut-off above which heterogeneity is considered
high [4–6], and in several cases, meta-analysis could not be per-
formed because of the high heterogeneity found among primary
studies [7].
In addition to the heterogeneity issue, clinical pharmacy ser-
vices are also complex health interventions that include a number
of interacting components that may act both independently or
interdependently to achieve a desired outcome [8]. Thus, isolating
these components and determining which of them are the most
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meaningful for the intervention outcome obtained can be trouble-
some. In geriatrics, previous authors have developed a graphical
method to facilitate the reporting of process evaluation’s results of
complex multi-component interventions focusing on health care
interventions for elderly people [9]. The authors argued that such
an instrument might aid the critical appraisal of primary studies as
well as performing mixed-method systematic reviews of hetero-
geneous and complex interventions [9].
Another limiting aspect of conducting systematic reviews and
meta-analyses in the pharmacy field is that generally the interven-
tions performed by the pharmacist are poorly and inconsistently
described in primary studies, as pointed out by numerous authors
[2,10,11]. In order to address the issue of the lack of an in-depth
intervention description, a tool to characterize the components of
pharmacist interventions performed as part of clinical pharmacy
services – DEPICT (Descriptive Elements of Pharmacist Interven-
tion Characterization Tool) – was recently developed [12]. The
tool contained 54 items where each item was designed to reflect
components of pharmacists’ interventions. DEPICT was created
with the aim of allowing the retrospective analysis of published
studies, facilitating comparisons among them, but also as a way of
assisting authors when reporting pharmacist interventions to
ensure their reproducibility in practice [12].
After the experience acquired with the application of DEPICT
to studies describing pharmacists’ interventions in the manage-
ment of patients with chronic kidney disease, a need to create an
improved version of the instrument arose [13]. In that study, the
authors identified several gaps with some interventions that were
specific of this setting not being appropriately reflected on the
instrument, namely studies describing therapeutic protocol imple-
mentation by pharmacists [13]. In addition, DEPICT 1 was devel-
oped based on the intervention description available in 49
systematic reviews and not in their respective 269 primary studies,
which further contributed to a less detailed description of clinical
pharmacy services. Therefore, the aim of the present study was to
create an improved version of DEPICT (i.e. DEPICT 2) to better
characterize clinical pharmacy services in order to ensure consist-
ent reporting, therefore enhancing reproducibility of interventions
in clinical practice.
Methods
The development of DEPICT 2 was carried out in three phases: (1)
creation of a preliminary version of DEPICT 2; (2) achievement of
the final version of DEPICT 2; and (3) comparison of the final
version of DEPICT 2 against DEPICT 1.
Preliminary version of DEPICT 2
A qualitative analysis of the description of pharmacist interven-
tions contained in the 269 randomized controlled trials (RCTs)
included in the 49 systematic reviews that served as the basis for
the creation of DEPICT 1 was performed in September 2012. A
thematic content analysis was performed and components of phar-
macist interventions described in the 269 studies were coded and
ordered by thematic similarity to reduce data to highly conceptu-
alized themes. During the coding process carried out by one of the
authors (C.J.C.), a permanent debate was maintained with three
other authors (F.F-L., T.M.S. and T.T.S.) to ensure an appropriate
grouping of pharmacist interventions. This process resulted in the
addition of more items to the original instrument and subdivision
of others to better describe the components of the interventions
performed as part of clinical pharmacy services. Data analysis was
performed with the support of N-vivo 8 software (http://
www.qsrinternational.com).
Final version of DEPICT 2
The preliminary version of DEPICT 2 was applied independently
by two authors (I.R. and D.C.F.) to a random sample of the pre-
vious 269 RCTs analysed between October and December 2012.
Sample size was calculated using a two-tailed test, an estimate
proportion of positive rating for each item of 0.30, a minimum
acceptable value of kappa of 0.70, a statistical power of 80%, and
assuming a null hypothesis value of kappa to be 0.40. The number
of RCTs required to detect a statistically significant kappa value
(P < 0.05) was thus estimated to be 85. These 85 articles were
selected out of the 269 RCTs using a random number list generator
(randomizer.org) and the final 85 articles randomized corre-
sponded to 82 different studies. In order to ensure homogeneity
in the analysis of the 82 studies by the two authors, a manual
with clear instructions for item interpretation (available at
depictproject.org) was developed prior to the assessment.
To assess the reliability of the instrument, the inter-rater agree-
ment kappa coefficient was calculated for all dichotomous vari-
ables and the intraclass correlation coefficient (ICC) for discrete or
continuous variables. To avoid potential effects of a low compo-
nent prevalence on kappa results, the prevalence-adjusted bias-
adjusted kappa (PABAK) was used over kappa [14]. PABAK was
calculated using the software WinPepi version 11.25 (http://
www.brixtonhealth.com). As standards for strength of agreement
for PABAK coefficient, we assumed <0 = poor; 0–0.20 = slight;
0.21–0.40 = fair; 0.41–0.60 = moderate; 0.61–0.80 = substantial;
and 0.81–1.00 = almost perfect agreement [15]. As standards for
strength of agreement for ICC, we adopted cut-offs similar to those
used for the kappa statistic, since they represent directly analogous
measures: 0–0.2 = poor agreement; 0.3–0.4 = fair agreement; 0.5–
0.6 = moderate agreement; 0.7–0.8 = strong agreement; and
>0.8 = almost perfect agreement [15].
After performing the reliability analysis, items with a PABAK
or an ICC value under or equal to 0.60 had their interpretation
reassessed and wording modified accordingly, and the instructions
for item scoring in the manual were adapted. The two authors that
performed the reliability analysis were kept blind to this assess-
ment and conducted a subsequent analysis of the RCTs using the
modified version of the manual. PABAK and ICC coefficients
were then recalculated and, after this second analysis, only items
with a PABAK or ICC value above 0.60 were included in the final
version of DEPICT 2.
Comparison of the final version of DEPICT 2
against DEPICT 1
A comparison of the final version of DEPICT 2 was performed
against the published version of DEPICT 1. The same authors that
performed the reliability analysis for DEPICT 2 (I.R. and D.C.F.)
applied DEPICT 1 independently to the same 82 studies. The
number of items checked for a given study when applying both
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DEPICT 1 and DEPICT 2 was compared and the frequency of
items contained exclusively in DEPICT 2 was evaluated. The
Wilcoxon signed-rank test was used to compare the two versions
of DEPICT on the same sample of studies.
Results
Preliminary version of DEPICT 2
Following the qualitative analysis of the intervention description
in the 269 RCTs, 92 more items were added to the previous 54 in
DEPICT 1. The original structure of DEPICT was also modified
and the number of domains was reduced from 12 to 11. While
DEPICT 1 was created as a list of items containing a single column
to fill out with a yes/no answer, DEPICT 2 contains two columns
to encompass interventions targeting both patients/caregivers and
health care professionals. In addition, some items in DEPICT 2
can be checked for both patients/caregivers and health care pro-
fessionals (domains 1, 2 and 6 to 10), others can only be checked
for patients/caregivers (domain 11), and other items describe
elements of the intervention that are independent of the recipient
(domains 3, 4 and 5). A set of additional items were included in
DEPICT 2 to ensure that none of the domains would remain blank
(items 2.10, 3.04, 4.15, 5.16, 6.08, 7.10, 8.09 and 11.01). A
summary of the main differences between each version of
DEPICT is outlined in Table 1.
Final version of DEPICT 2
DEPICT 2 preliminary version was ultimately applied to 82
studies given that in three instances, two different articles were
part of the same study [16–20]. The studies analysed were pub-
lished between 1977 and 2009 and were performed in the follow-
ing countries: United States (n = 50), United Kingdom (n = 8),
Australia (n = 6), Canada (n = 4), the Netherlands (n = 3), Chile
(n = 2), India (n = 2), Belgium (n = 1), Brazil (n = 1), China
(n = 1), Germany (n = 1), Sweden (n = 1), Thailand (n = 1) and
United Arab Emirates (n = 1).
After applying DEPICT 2 by the two raters to the 82 studies, the
mean PABAK value obtained for the dichotomous variables was
0.85 denoting an ‘almost perfect’ agreement (95% CI 0.82–0.87).
The PABAK value was less than or equal to 0.60 for nine items
(6.3%) and the minimum value obtained was 0.14. For the remain-
ing 133 items, 40 (30.0%) presented a PABAK value comprised
between 0.61 and 0.80 (substantial agreement) and 93 items
(70.0%) between 0.81 and 1.0 (almost perfect agreement). After
rewriting the nine items that presented a PABAK equal to or lower
than 0.60 and modifying their description in the manual, the recal-
culated mean PABAK value obtained was 0.87 (95% CI 0.85–
0.89). Finally, 45 items (31.7%) presented a PABAK value
between 0.61 and 0.80 (substantial agreement) and 97 (68.3%)
between 0.81 and 1.0 (almost perfect agreement).
For the discrete/continuous variables, the mean ICC value in the
first assessment was 0.46 (95% CI 0.21–1.14), which can be clas-
sified as fair agreement. The ICC value was less than or equal to
0.60 for two items (50.0%) and the minimum value obtained was
0.09. The remaining two items (50.0%) presented ICC values of
0.64 and 0.98 (moderate and almost perfect agreement, respec-
tively). After the second assessment, the mean ICC was 0.88 (95%
CI 0.62–1.14) and all items presented an ICC value between 0.64
and 0.98. The overall results of PABAK and ICC for each round of
assessment are presented in Supporting Information Appendix S1.
Table 1 Summary of the main differences
between DEPICT 1 and DEPICT 2
DEPICT 1 DEPICT 2
Source of information
extraction
49 systematic reviews 269 randomized controlled trials
No. items 54 146
(53 dichotomous variables
and 1 discrete variable)
(142 dichotomous variables and 4
discrete variables)
No. domains 12 11
Domain designation A. Contact with the patient
B. Timing of intervention
C. Setting of intervention
D. Target population
E. Clinical data sources
F. Assessment
G. Pharmacist’s autonomy
H. Pharmacist
communication
I. Support resources
provided by pharmacist
J. Education and
counselling
L. Follow-up
M. Other actions
1. Contact with recipient
2. Setting
3. Focus of intervention
4. Clinical data sources
5. Variables assessed
6. Action(s) taken by the pharmacist
7. Timing of action(s)
8. Materials that support actions
9. Repetition
10. Communication with recipient
11. Changes in therapy and lab tests
Target of the intervention Patients Patients/caregivers and health care
professionals
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At the end of this process, DEPICT 2 conserved the same
number of items and domains as the preliminary version, only
with minor changes to the wording and to the scoring manual
(Appendix A).
Comparison of the final version of DEPICT 2
against DEPICT 1
Globally, the score obtained by applying DEPICT 2 to the 82
RCTs was higher compared with the score obtained when using
DEPICT 1 (24.0 versus 13.4, Wilcoxon signed-rank test,
P < 0.001). The mean difference between items checked in the two
versions of DEPICT (DEPICT 2 – DEPICT 1) was 10.6 (95% CI
9.6–11.6), meaning that approximately 11 (85%) more compo-
nents of pharmacist interventions were identified in the new
version of DEPICT. In the 50 interventions targeting patients only,
the scores obtained were 18.0 (95% CI 16.8–19.3) and 11.2 (95%
CI 10.0–12.4) when using DEPICT 2 and DEPICT 1, respectively
(Wilcoxon signed-rank test, P < 0.001). For the 11 interventions,
where pharmacists established contact with the health care profes-
sional alone, the score obtained when using DEPICT 2 was 18.6
(95% CI 16.3–21.0) and 6.1 (95% CI 4.0–8.1) when using
DEPICT 1 (Wilcoxon signed-rank test, P < 0.001).
Discussion
Our study aimed to improve the initial version of DEPICT to better
describe the components of clinical pharmacy services in order to
enhance the reproducibility of interventions in clinical practice by
ensuring their consistent reporting. To accomplish this goal, we
analysed pharmacists’ interventions described in 269 RCTs that
were included in the 49 systematic reviews used to develop
DEPICT 1, rather than just analysing the description of the inter-
ventions from systematic reviews. This allowed the collection of
more detailed and complete information on the clinical pharmacy
service provided.
A final version of DEPICT 2 was obtained with the revised tool
comprising 11 domains and 146 items and including an extensive
list of components contemplating all variables that could be part of
a complex clinical pharmacy service. Some items were common
between the two versions of the tool, but most of the items
included in DEPICT 2 arose from a new analysis. The structure of
DEPICT 2 was designed to allow the analysis of studies describing
pharmacists’ interventions targeting both patients/caregivers and
health care professionals. After the second reliability assessment,
the mean PABAK value obtained reflected an almost perfect agree-
ment and ICC values presented a moderate to almost perfect agree-
ment. These results show that the instrument is reliable and that the
manual created to ensure consistency in the analysis served its
purpose.
Following the incorporation of new items and the subdivision of
pre-existing ones, studies assessed with DEPICT 2 had approxi-
mately 11 more components checked to describe pharmacists’
interventions, which suggests a higher discriminating ability of
this version. This applies to interventions targeting both patients
and health care professionals. While there was an evident differ-
ence between scores of studies describing interventions targeting
only patients or targeting only health care professionals with
DEPICT 1 (11.2 versus 6.1), this difference was neutralized with
DEPICT 2 (18.0 versus 18.6). This reinforces the existing need to
restructure DEPICT 1 to address its limitation of not including
pharmacy services targeting health care professionals alone.
Therefore, the creation of DEPICT 2 allowed an equivalent iden-
tification of clinical pharmacy service components targeting both
patients and health care professionals.
Besides its utility in helping isolate components of clinical
pharmacy services involving complex interventions, DEPICT can
also be a useful means of identifying specific actions that do not
characterize actual clinical pharmacist interventions but simple
actions that could be delivered by a lay caregiver. As an example,
one study in which the role of the pharmacist was to provide a
special medication container to the patient with no further action
the score obtained with DEPICT 1 and DEPICT 2 was the same
[21]. Another study in which the pharmacist intervention was
simply to deliver a medication compliance device to the patient
scored similarly in the two versions [22]. These two situations
demonstrate that the simpler the intervention, the smaller the dif-
ference between the two versions of DEPICT. In cases like these,
several domains of the instrument remained in blank, and there-
fore, the total number of points scored was low. Another explana-
tion for the presence of blank items in some domains of DEPICT
can be related to the poor intervention description.
As discussed for the creation of DEPICT 1, the development
and validation of a universal tool to characterize clinical pharma-
cist interventions is a critical step to identify the most powerful
components of a complex intervention, that is, components that
represent a greater contribution to the outcomes obtained [12]. An
improved and more specific version of DEPICT will allow a better
discrimination of the intervention components of clinical phar-
macy services. Additionally, the retrospective application of
DEPICT 2 to pharmacy studies will likely result in a better under-
standing of the pharmacy service as a whole, facilitating inter-
study comparisons and contributing to the reproducibility of the
interventions from pharmacy practice studies to the real world.
Using DEPICT 2 as a reference guide to reporting pharmacist
interventions in future studies could not only be a way of ensuring
their reproducibility, but also a way of reducing the heterogeneity
obtained in meta-analyses when gathering data from pharmacy
studies [4–6]. DEPICT 2 could be considered a new parameter to
evaluate biases and increase the applicability of the evidence gen-
erated in meta-analyses.
A limitation of our study is that we based the analysis and
identification of pharmacist intervention components on the
description of services provided by the authors, which could be an
issue in studies with poor intervention description. We are aware
that efforts are being made to assess the quality of reporting of
specific interventions such as those involving a behavioral change
[23]. Tools designed for this end are likely more detailed for this
type of interventions than DEPICT; however, our aim was to create
a valid tool for any type of intervention and not just those
behavioral related. Furthermore, the use of these specific tools
would be useless to analyse complex interventions comprising
both behavioral changes and other types of interventions. As
strengths of this study, it can also be said that the subset of RCTs
used was international and was based on a comprehensive litera-
ture review, and that a high inter-rater reliability was obtained.
In conclusion, DEPICT 2 is an improved version of DEPICT 1,
and it comprises 146 items grouped in 11 domains, as opposed to
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the prior 54-item, 12-domain version. DEPICT 2 allows the analy-
sis of studies describing pharmacists’ interventions targeting both
patients/caregivers and health care professionals, whereas this dis-
tinction was not clearly identifiable in DEPICT 1. DEPICT 2
presents, on average, almost perfect agreement results in the reli-
ability analysis and was proved to better discriminate more com-
ponents of pharmacist interventions performed as part of clinical
pharmacy services. The better discriminating ability of DEPICT 2
will likely ensure consistent reporting of interventions when used
in early stages of report preparation and therefore contribute to
facilitate the reproducibility of the intervention in clinical practice.
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Appendix A
Descriptive Elements of Pharmacist Intervention Characterization Tool – DEPICT 2
Instrucons
Examples:
0.00 Who the pharmacist contacts as part of the service
RECIPIENT
A. PATIENT /
CAREGIVER
B. HEALTH CARE
PROFESSIONAL
Paent
Counseling
Academic Detailing
Instrucons: Check the cells that correspond to the components of the pharmacist's intervenon. A checked cell
represents "Yes". An empty cell represents "No or Not Reported". HCP= Health Care Professional
1. CONTACT WITH RECIPIENT: how the contact with the recipient occurs
1.01 One-on-one contact
1.02 Contact with group
2. SETTING: where the recipient received the service
2.01 Community pharmacy
2.02 Hospital bedside
2.03 Emergency department
2.04 Hospital pharmacy
2.05 Ambulatory / Primary care seng
2.06 HCP office
2.07 Recipient's home
2.08 Nursing home / Long-term care facility
2.09 Public places / Classrooms
2.10 Other seng clearly stated, not previously included
3. FOCUS OF INTERVENTION: characteriscs of the paent who benefits indirectly or directly from the intervenon
3.01 On a specific medical condion
3.02 On a specific medicaon or pharmacological class or dosage form
3 03 On a pre-specified sociodemographic paent´s characteriscs.
3.04 Without any disease, pharmacological or sociodemographic restricon
4. CLINICAL DATA SOURCES: where the pharmacist obtains the informaon for paent´s assessment
4.01 Drug prescripon orders
4.02 Pharmacy records / Pharmacy computer system
4.03 Point-of-care tesng
4.04 Medicaon list or brown bag data
4.05 Paent self-monitoring data
4.06 Adherence measuring tools
4.07 Physical / Funconal assessment procedure or test
4.08 Cognive / Mental assessment test
4.09 Laboratory tests / Therapeuc drug monitoring
4.10 Paent interview (not including assessment procedures or tests)
4.11 Medical records
4.12 Discharge or referral leer
4.13 Direct contact with HCP
4.14 Aggregated clinical databases / Alert systems
4.15 Other clearly stated clinical data sources, not previously included
5 VARIABLES ASSESSED: parameters evaluated by pharmacist to construct intervenon.
5.01 Drug selecon (Rx, OTC or other)
5.02 Medicaon / Therapy effecveness
5.03 Medicaon safety
5.04 Paent / Caregiver educaonal needs / Beliefs
5.05 HCP informaon needs
5.06 Medicaon adherence
5.07 Medicaon list / History accuracy
5.08 Paent nutrion or lifestyle
5.09 Screening results
5.10 Costs of treatment
5.11 Medicaon accessibility / Availability
5.12 Expired or improperly stored medicaon
5.13 Dispensing or administraon errors
5.14 Laboratory tests requirements
5.15 Legal or administrave requirements
5.16 Other clearly stated variable(s) assessed, not previously included
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6. ACTION(S) TAKEN BY PHARMACIST: wha s done to address the idenfied problems
6.01 Structured Educaonal Program
6.02 Drug informaon or paent counseling
6.03 Reminders / Noficaon about non-compliance
6.04 Referral to other HCP or service
6.05 Change or suggeson for change in therapy / Lab tests order
6.06 Update of paent's medicaon list
6.07 Monitoring results report
6.08 Other clearly stated acon(s), not previously included
7. TIMING OF ACTION(S) when the acon takes place for each recipient
7 01 On or during paent admission.
7.02 On paent discharge
7.03 First weeks aer paent discharge
7.04 Inter / Intra paent health care facility transfer
7.05 Aer an acute paent event or exacerbaon
7.06 Medicaon dispensing
7.07 Scheduled appointment
7.08 At any me
7.09 New or changed prescripon
7.10 Other clearly stated ming of acon(s), not previously included
8. MATERIALS THAT SUPPORT ACTION(S): Items developed or provided as part of the service
8.01 Discharge or referral leer
8.02 Educaonal materials / Leaflets / Wrien acon plan
8.03 Medicaon compliance device/ Administraon aid device
8.04 Medicaon list / Medicaon schedule / Medicaon report
8.05 Paent diary / Health diary
8.06 Guidelines / Clinical procotols / Evidence chart
8.07 Self-monitoring device
8 08 Auxiliary labels / Pictorial instrucons / Wrien reminders.
8.09 Other materials developed or provided, not previously included
9. REPETITION: Recurrence and frequency of acons and contacts with recipient
Acon recurrence
9.01 Acon(s) described in item 6 performed in one contact
9.02 Acon(s) described in item 6 performed in mulple contacts
Frequency of contacts
9.03 Number of contacts with recipient during service
9.04 Intervenon duraon per recipient (in days)
10. COMMUNICATION WITH RECIPIENT
Method
10.01 Face-to-face
10.02 Wrien (including web-based)
10.03 Telephone
10.04 Video conference
Distribuon of contacts during intervenon
10.05 Only in person
10.06 Mainly in person with some remote contact
10.07 Equally in person and remotely
10.08 Mainly remotely with some contact in person
10.09 Only remotely
11. CHANGES IN THERAPY AND LAB TESTS
11.01 Not applicable (Check if item A.6.05 was not selected or only deals with non-prescripon meds.)
Medicaon and Lab tests
11.02 Autonomy to start medicaon
11.03 Autonomy to suspend medicaon
11.04 Autonomy to change medicaon dosage
11.05 Autonomy to order laboratory tests
Capability to make changes in prescripon medicaon or lab tests
11.06 Changes or lab tests orders with restricons (dependent prescribing model)
11.07 Changes or lab tests orders without restricons (independent prescribing model)
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